静脉注射免疫球蛋白治疗疼痛性特发性小纤维神经病
这项双盲随机对照试验纳入60例皮肤活检证实的特发性小纤维神经病患者,随机接受IVIG或安慰剂治疗。12周时IVIG组40%患者平均疼痛下降至少1分,安慰剂组为30%(p=0.588),差异无统计学意义;其他预设结局也无显著差异。IVIG对疼痛性I-SFN的疼痛无显著效果。
要点
- IVIG组40%患者疼痛下降≥1分,安慰剂组30%,差异无统计学意义。
- 一般健康状况、自主神经症状、整体功能与残疾等预设结局均无显著差异。
- 该研究提供I级证据表明IVIG不能显著减轻疼痛性I-SFN的疼痛。
核心结论
- IVIG治疗对疼痛性特发性小纤维神经病患者的疼痛无显著效果。
研究设计与样本
- IVIG起始剂量2 g/kg体重,安慰剂为0.9%盐水,随后每3周追加3次IVIG(1 g/kg)或安慰剂。
- IVIG组30例、安慰剂组30例,两组各29例完成试验。
主要发现
- 12周时IVIG组40%患者平均疼痛较基线下降至少1分,安慰剂组为30%(p=0.588,OR 1.56,95%CI 0.53-4.53)。
- 一般健康状况、自主神经症状、整体功能与残疾等其他预设结局均无显著差异。
关键数值与推荐
- 主要结局为12周时疼痛强度数值评定量表评分较基线变化1分。
- IVIG组疼痛下降≥1分比例40% vs 安慰剂组30%,p=0.588,OR 1.56,95%CI 0.53-4.53。
临床怎么用
- 不推荐对疼痛性特发性小纤维神经病患者使用IVIG以减轻疼痛。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This is the first double-blind randomized controlled trial evaluating the efficacy and safety of IV immunoglobulin (IVIG) vs placebo in patients with idiopathic small fiber neuropathy (I-SFN). METHODS: Between July 2016 and November 2018, 60 Dutch patients with skin biopsy-proven I-SFN randomly received a starting dose of IVIG (2 g/kg body weight) or matching placebo (0.9% saline). Subsequently, 3 additional infusions of IVIG (1 g/kg) or placebo were administered at 3-week intervals. The primary outcome was a 1-point change in Pain Intensity Numerical Rating Scale score at 12 weeks compared to baseline. RESULTS: Thirty patients received IVIG, and 30 received placebo. In both groups, 29 patients completed the trial. In 40% of patients receiving IVIG, the mean average pain was decreased by at least 1 point compared to 30% of the patients receiving placebo (p = 0.588, odds ratio 1.56, 95% confidence interval 0.53-4.53). No significant differences were found on any of the other prespecified outcomes, including general well-being, autonomic symptoms, and overall functioning and disability. CONCLUSIONS: This randomized controlled trial showed that IVIG treatment had no significant effect on pain in patients with painful I-SFN. TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov Identifier: NCT02637700, EudraCT 2015-002624-31. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that for patients with painful I-SFN, IVIG did not significantly reduce pain compared to placebo.
引用
- Geerts M, de Greef BTA, Sopacua M, et al. Intravenous Immunoglobulin Therapy in Patients With Painful Idiopathic Small Fiber Neuropathy. Neurology. 2021. PMID: 33766992. doi:10.1212/WNL.0000000000011919
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。